These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. Haratani K; Hayashi H; Chiba Y; Kudo K; Yonesaka K; Kato R; Kaneda H; Hasegawa Y; Tanaka K; Takeda M; Nakagawa K JAMA Oncol; 2018 Mar; 4(3):374-378. PubMed ID: 28975219 [TBL] [Abstract][Full Text] [Related]
23. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392 [TBL] [Abstract][Full Text] [Related]
24. Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. Ishihara H; Takagi T; Kondo T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K Med Oncol; 2019 Mar; 36(4):35. PubMed ID: 30879157 [TBL] [Abstract][Full Text] [Related]
25. The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab. Yoshimura A; Nagahara A; Ishizuya Y; Yamamoto Y; Hatano K; Kawashima A; Nakai Y; Nakayama M; Nishimura K; Nonomura N; Kato T Clin Exp Med; 2024 May; 24(1):111. PubMed ID: 38780659 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma. Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960 [TBL] [Abstract][Full Text] [Related]
27. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM Curti B; Daniels GA; McDermott DF; Clark JI; Kaufman HL; Logan TF; Singh J; Kaur M; Luna TL; Gregory N; Morse MA; Wong MKK; Dutcher JP J Immunother Cancer; 2017 Dec; 5(1):102. PubMed ID: 29254506 [TBL] [Abstract][Full Text] [Related]
28. Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with Kobayashi M; Numakura K; Hatakeyama S; Muto Y; Sekine Y; Sasagawa H; Kashima S; Yamamoto R; Koizumi A; Nara T; Saito M; Narita S; Ohyama C; Habuchi T Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35885987 [TBL] [Abstract][Full Text] [Related]
29. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients. Kankkunen E; Penttilä P; Peltola K; Bono P Acta Oncol; 2022 Oct; 61(10):1240-1247. PubMed ID: 35905053 [TBL] [Abstract][Full Text] [Related]
30. Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias. Ishidoya M; Makiguchi T; Tanaka H; Miura T; Nunomura Y; Miura D; Morimoto T; Hasegawa Y; Taima K; Tasaka S Lung Cancer; 2024 Jun; 192():107790. PubMed ID: 38696920 [TBL] [Abstract][Full Text] [Related]
38. Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Paderi A; Giorgione R; Giommoni E; Mela MM; Rossi V; Doni L; Minervini A; Carini M; Pillozzi S; Antonuzzo L Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670634 [TBL] [Abstract][Full Text] [Related]
39. Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab. Mizutani K; Ito T; Takahara K; Ando R; Ishihara T; Yasui T; Shiroki R; Miyake H; Koie T Medicine (Baltimore); 2021 Apr; 100(13):e25402. PubMed ID: 33787647 [TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab. Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]